Cargando…
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations
Developing a strategy to specifically kill cancer cells without inducing obvious damage to normal cells may be of great clinical significance for cancer treatment. In the present study, we developed a new precise personalized strategy named "i-CRISPR" for cancer treatment through adding DN...
Autores principales: | Jiang, Junfeng, Chen, Yuanyuan, Zhang, Li, Jin, Qishu, Wang, Liujun, Xu, Sha, Chen, Kexin, Li, Li, Zeng, Tao, Fan, Xingfei, Liu, Tingting, Li, Jiaxi, Wang, Jinjiang, Han, Chaofeng, Gao, Fu, Yang, Yanyong, Wang, Yue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380384/ https://www.ncbi.nlm.nih.gov/pubmed/35974394 http://dx.doi.org/10.1186/s12943-022-01612-x |
Ejemplares similares
-
Optimization of Cas9 RNA sequence to reduce its unexpected effects as a microRNA sponge
por: Jiang, Junfeng, et al.
Publicado: (2022) -
Efficient CRISPR/Cas9-mediated Targeted Mutagenesis in Populus in the First Generation
por: Fan, Di, et al.
Publicado: (2015) -
PAI-1 Polymorphisms Have Significant Associations With Cancer Risk,
Especially Feminine Cancer
por: Wang, Jiaxi, et al.
Publicado: (2021) -
Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics
por: Bhattacharjee, Rudrarup, et al.
Publicado: (2022) -
A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine
por: Huang, Wei, et al.
Publicado: (2021)